Treatment With Crizotinib Single Patient Expanded Access IND 134375

NCT03085186 | Unknown

• 1 other identifier: PRO17030033
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Two year old male with a new diagnosis of Inflammatory Myofibroblastic Tumour. The patient presented with 2 months of intermittent fever and 1-2 weeks of abdominal distention and constipation. An abdominal mass was palpable on exam and US concerning was for neoplasm of abdomen. Treatment with Crizotinib will be utilized to reduce the size of the lesion and create more optimal tissue plains between vital structures prior to attempted surgical resection would greatly reduce potential morbidity for this patient.

Conditions

Inflammatory Myofibroblastic Tumour

Interventions

Crizotinib DRUG

Eligibility Criteria

• Age: 2 Years - 2 Years
• Sex: male
• Age Groups: Child (0-17)

You may qualify if:

• This treatment plan is intended for the use of Crizotinib in the treatment of a single patient with Inflammatory Myofibroblastic Tumour

You may not qualify if:

• Not applicable as Expanded Access only includes one patient

Sponsors & Collaborators

• Jean M. Tersak, M.D.: lead
• Pfizer: collaborator

MeSH Terms

Conditions

Granuloma, Plasma Cell

Interventions

Crizotinib

Condition Hierarchy (Ancestors)

Granuloma; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Piperidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Aminopyridines; Pyridines

Study Design

• Study Type: expanded access
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: March 14, 2017
• First Posted: March 21, 2017
• Last Updated: August 29, 2017

Record last verified: 2017-08